Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: CEO
Company: Immunophage Biotech Co., Ltd.
个人简介:
Dr. Guohuang Fan, President and CEO of Immunophage Biotech Co., Ltd., received his MD and Ph.D. in Shanghai Jiao Tong University School of Medicine in 1996. After 6 years of postdoctoral training in Chinese Academy of Sciences, University of Wuerzburg, and Vanderbilt University, he was appointed as Research Assistant Professor in Vanderbilt University School of Medicine in 2002. In 2004, Dr. Fan was appointed as Assistant Professor (tenure track) in Meharry Medical College, and secondary Assistant Professor in Vanderbilt University School of Medicine. He was promoted to Associate Professor in Meharry Medical College in 2007, and moved to Virginia Commonwealth University School of Medicine as Associate Professor in 2008. In 2010, Dr. Fan Joined GSK R&D China as an Associate Director, and was appointed as Adjunct Professor in Tongji University. He joined Nanchang University as Vice Dean in the School of Translational Medicine, and Director of Biomedical Research Center in 2016, when he founded Immunophage Biotech Co., Ltd. Dr. Fan is an expert in cancer biology and neurobiology, with over 60 papers published in peer-reviewed international journals and 20 patents. Dr, Fan is the winner of the National Natural Science Award (2002), Chinese Medical Science Award (2001), and Specialized Neuroscience Research Award form NIH, USA (2007).He was the scholar of 'Alexander Von Humboldt fellowship', Germany, the scholar of 'One-hundred Talent Program', Chinese Academy of Sciences.
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Chairman&CEO
Company: BioNova Pharmaceuticals Ltd.
个人简介:
Ye Hua, MD, MPH is the founder and CEO of BioNova Pharmaceuticals, a start-up biopharmaceutical company that is dedicated to the development and commercialization of innovative medicines for the treatment of cancers and other diseases with high unmet medical needs. The company focuses on building a robust pipeline through internal R&D programs, collaborations with global partners, and selective license and acquisitions. With a highly capable management team, cutting edge biotechnology, and substantial funding, BioNova is committed to delivering high quality innovative medicines to the patients in China and globally.Dr. Hua is a senior drug developer who has 20+ years’ global clinical development and new drug registration experience with track records in the pharmaceutical industry. Prior to building up BioNova, Dr. Hua was Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchmed, a leading R&D biotech company headquartered in Shanghai China.
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Partner
Company: Pivotal bioVenture Partners China
个人简介:
Dianna joined Pivotal China in 2018 as a Partner. Dianna has 20+ years of healthcare expertise; previously as core healthcare investment member at Fidelity Asia Growth Partners and FountainVest Partners. Prior to that, Dianna worked as Vice President at Boehringer Ingelheim China in charge of Business Development and New Product Planning, and Engagement Manager at McKinsey’s China and US offices specializing in healthcare sector.Dianna graduated from Wharton Business School with an MBA degree in 2004.
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Co-Founder, Chairman, CEO
Company: OnCusp Therapeutics
个人简介:
Bing Yuan, PhD, MBACo-Founder, Chairman and CEO, OnCusp TherapeuticsDr. Bing Yuan is an entrepreneur and a seasoned business executive in business development and licensing (BD&L), marketing and new product strategy. He has made significant contributions to 13 approved global oncology drugs at various stages of product life cycle, including blockbusters such as Keytruda and Glivec. Before founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals.  As a senior executive from the beginning, he helped to build the company from startup to successful IPO and then becoming a commercial stage biopharma. At CStone, he established and managed over 10 departments, such as BD&L, public relations, R&D project management and commercial organization.  He successfully reached close to 10 strategic partnerships with Pfizer, Bayer, Blueprint, Agios, EQRx, etc. Before joining CStone in November 2016, he spent 22 years in the USA. He was Executive Director and Global Lead of Oncology BD&L at Merck (MSD), Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, Global Oncology Marketing Lead at Eisai, and Product Manager at Thermo-Fisher. He successfully led or contributed to over 40 M&A, licensing and Keytruda clinical collaboration deals. As a core member of the global project team (GPT), he played a key role in designing development strategy for 5 oncology drugs. He used to lead Glivec and Afinitor brand life cycle strategy and participated in global launch of Zykadia in ALK+ lung cancer. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and B.S. of Biochemistry from Nanjing University.